Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Novo Nordisk A/S
NOVANovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Analytics
Preço Alvo de Wall Street
148.23 USDRácio P/E
43.5503Rendimento de dividendos
1.11 %Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave NOVA
Análise de Dividendos NOVA
Crescimento de dividendos em 5 anos
62 %Crescimento contínuo
5 anosTaxa de pagamento em média de 5 anos
19 %Histórico de Dividendos NOVA
Avaliação de ações NOVA
Relatório NOVA
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |